New combo therapy targets lung cancer brain tumors in early trial
NCT ID NCT07413952
First seen Mar 02, 2026 · Last updated May 13, 2026 · Updated 7 times
Summary
This study tests a new targeted drug (limertinib) combined with radiation therapy as a first treatment for people with a specific type of lung cancer (EGFR-mutant non-small cell lung cancer) that has spread to the brain. The goal is to see if the combination can better control brain tumors and delay their growth. About 45 adults aged 18-75 will take part in this early-phase, single-arm trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong
Guangzhou, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.